Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Stage of Development | 8 | 1 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Therapy Area | 9 | 1 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Indication | 10 | 2 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Companies | 14 | 3 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Universities/Institutes | 17 | 2 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Therapeutics Assessment | 19 | 5 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 1 |
| Assessment by Route of Administration | 21 | 1 |
| Assessment by Molecule Type | 22 | 2 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Companies Involved in Therapeutics Development | 24 | 7 |
| Ascentage Pharma Group Corporation, Ltd. | 24 | 1 |
| Astex Pharmaceuticals, Inc. | 25 | 1 |
| Bristol-Myers Squibb Company | 26 | 1 |
| Debiopharm International SA | 27 | 1 |
| F. Hoffmann-La Roche Ltd. | 28 | 1 |
| Novartis AG | 29 | 1 |
| Takeda Pharmaceutical Company Limited | 30 | 1 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Drug Profiles | 31 | 17 |
| ASTX-660 Drug Profile | 31 | 1 |
| Debio-1143 Drug Profile | 32 | 3 |
| FL-118 Drug Profile | 35 | 2 |
| LCL-161 Drug Profile | 37 | 2 |
| SM-1200 Drug Profile | 39 | 1 |
| Small Molecule 2 to Inhibit XIAP for Oncology Drug Profile | 40 | 1 |
| Small Molecule to Inhibit XIAP and c-IAP for Melanoma Drug Profile | 41 | 1 |
| Small Molecule to Inhibit XIAP for Oncology Drug Profile | 42 | 1 |
| Small Molecules to Inhibit XIAP for Oncology Drug Profile | 43 | 1 |
| Synthetic Peptides to Inhibit XIAP for Oncology Drug Profile | 44 | 1 |
| T-3256336 Drug Profile | 45 | 1 |
| xaripin D Drug Profile | 46 | 1 |
| xaripin P Drug Profile | 47 | 1 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Dormant Projects | 48 | 3 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Discontinued Products | 51 | 1 |
| E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Featured News &Press Releases | 52 | 11 |
| Jun 07, 2016: Debiopharm International initiates clinical Phase II study evaluating Debio 1143 in Ovarian Cancer | 52 | 1 |
| Jun 02, 2016: FDA grants Orphan Drug Designation to Debiopharm International SA s IAP inhibitor Debio 1143 in the treatment of ovarian cancer | 52 | 1 |
| Dec 08, 2015: EMA grants Orphan Drug Designation to Debiopharm International s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer | 53 | 1 |
| Nov 03, 2015: Debiopharm International presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143 at the 27th EORTC-NCI-AACR symposium in Boston | 53 | 1 |
| Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies | 54 | 1 |
| Apr 16, 2015: Debiopharm International announces results of key oncology program, Debio 1143 at 2015 AACR Conference | 54 | 1 |
| Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer | 55 | 2 |
| Nov 18, 2014: Debiopharm Group Presents Advances Of key Oncology Product On Debio 1143 Clinical Program At The 26th EORTC-NCI-AACR Symposium In Barcelona | 57 | 1 |
| May 28, 2014: Debiopharm tp present data on Debio 1143 at the 50th ASCO Annual Meeting | 57 | 1 |
| Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent | 58 | 1 |
| Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent | 59 | 1 |
| Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies | 59 | 1 |
| Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent | 60 | 1 |
| Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent | 61 | 1 |
| Mar 29, 2011: University Of Michigan Researchers Discover New Cancer Drug, AT-406 | 61 | 2 |
| Appendix | 63 | 2 |
| Methodology | 63 | 1 |
| Coverage | 63 | 1 |
| Secondary Research | 63 | 1 |
| Primary Research | 63 | 1 |
| Expert Panel Validation | 63 | 1 |
| Contact Us | 63 | 1 |
| Disclaimer | 64 | 1 |